MedTrace Logo

Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer

NCT00271505 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2020-05-11

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to evaluate the effectiveness of Avastin® in combination with docetaxel and carboplatin in the treatment of lung cancer. The safety of this combination will also be studied.

Conditions

Interventions

DRUG

Bevacizumab (Avastin)

15 mg/kg intravenously (IV) every 3 weeks

DRUG

Carboplatin

AUC 6 IV every 3 weeks

DRUG

Docetaxel

75 mg/m2 IV every 3 weeks

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Vali Papadimitrakopoulou, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-05
Primary Completion
2017-07-27
Completion
2017-07-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00271505 on ClinicalTrials.gov